Sirtuins as modifiers of Parkinson's disease pathology

Journal of Neuroscience Research

Volumn 95, Issue 4, 2017, Pages 930-942

  Tang, Bor Luen ^a,b  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

leucine rich repeat kinase 2; LRRK2; parkin; Parkinson's disease; phosphatase and tensin homologue; PINK1; pTEN induced putative kinase 1; sirtuins

Indexed keywords

ALPHA SYNUCLEIN; ANTIOXIDANT; SIRTUIN; SIRTUIN 1; SIRTUIN 2; SIRTUIN 3; SIRTUIN 5; ENZYME ACTIVATOR; NEUROPROTECTIVE AGENT;

AUTOPHAGY; DISEASE ASSOCIATION; DISEASE COURSE; ENZYME ACTIVITY; EVIDENCE BASED MEDICINE; HUMAN; MICROTUBULE; MITOCHONDRIAL RESPIRATION; MITOPHAGY; NERVE CELL; NEUROPATHOLOGY; NEUROTROPISM; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN FUNCTION; REGULATORY MECHANISM; REVIEW; ANIMAL; CYTOLOGY; DISEASE MODEL; DRUG EFFECTS; ENZYMOLOGY; METABOLISM; PATHOLOGY;

ALPHA-SYNUCLEIN; ANIMALS; DISEASE MODELS, ANIMAL; ENZYME ACTIVATORS; HUMANS; NEURONS; NEUROPROTECTIVE AGENTS; PARKINSON DISEASE; SIRTUINS;

EID: 84992461103     PISSN: 03604012     EISSN: 10974547     Source Type: Journal    
DOI: 10.1002/jnr.23806     Document Type: Review

References (210)

1. Aerts L, De Strooper B, Morais VA. 2015. PINK1 activation-turning on a promiscuous kinase. Biochem Soc Trans 43:280–286.
2. Albani D, Polito L, Batelli S, De Mauro S, Fracasso C, Martelli G, Colombo L, Manzoni C, Salmona M, Caccia S, Negro A, Forloni G. 2009. The SIRT1 activator resveratrol protects SK-N-BE cells from oxidative stress and against toxicity caused by α-synuclein or amyloid-β (1–42) peptide. J Neurochem 110:1445–1456.
3. Alzheimer's Association. 2014. 2014 Alzheimer's disease facts and figures. Alzheimers Dement 10:e47–e92.
4. Amat R, Planavila A, Chen SL, Iglesias R, Giralt M, Villarroya F. 2009. SIRT1 controls the transcription of the peroxisome proliferator-activated receptor-gamma coactivator-1α (PGC-1α) gene in skeletal muscle through the PGC-1α autoregulatory loop and interaction with MyoD. J Biol Chem 284:21872–21880.
5. Ambasudhan R, Dolatabadi N, Nutter A, Masliah E, Mckercher SR, Lipton SA. 2014. Potential for cell therapy in Parkinson's disease using genetically programmed human embryonic stem cell-derived neural progenitor cells. J Comp Neurol 522:2845–2856.
6. Anandhan A, Tamilselvam K, Vijayraja D, Ashokkumar N, Rajasankar S, Manivasagam T. 2010. Resveratrol attenuates oxidative stress and improves behaviour in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) challenged mice. Ann Neurosci. 17:113–119.
7. Anderson RM, Bitterman KJ, Wood JG, Medvedik O, Sinclair DA. 2003. Nicotinamide and PNC1 govern life span extension by calorie restriction in Saccharomyces cerevisiae. Nature 423:181–185.
8. Aquilano K, Vigilanza P, Baldelli S, Pagliei B, Rotilio G, Ciriolo MR. 2010. Peroxisome proliferator-activated receptor gamma coactivator 1α (PGC-1α) and sirtuin 1 (SIRT1) reside in mitochondria: possible direct function in mitochondrial biogenesis. J Biol Chem 285:21590–21599.
9. Arduíno DM, Esteves AR, Cortes L, Silva DF, Patel B, Grazina M, Swerdlow RH, Oliveira CR, Cardoso SM. 2012. Mitochondrial metabolism in Parkinson's disease impairs quality control autophagy by hampering microtubule-dependent traffic. Hum Mol Genet 21:4680–4702.
10. Ariga H, Takahashi-Niki K, Kato I, Maita H, Niki T, Iguchi-Ariga SMM. 2013. Neuroprotective function of DJ-1 in Parkinson's disease. Oxid Med Cell Longev 2013:683920.
11. Atik A, Stewart T, Zhang J. 2016. Alpha-synuclein as a biomarker for Parkinson's disease. Brain Pathol 26:410–418.
12. Austin S, St-Pierre J. 2012. PGC1α and mitochondrial metabolism—emerging concepts and relevance in ageing and neurodegenerative disorders. J Cell Sci 125:4963–4971.
13. Baeza J, Smallegan MJ, Denu JM. 2016. Mechanisms and dynamics of protein acetylation in mitochondria. Trends Biochem Sci 41:231–244.
14. Baldelli S, Aquilano K, Ciriolo MR. 2014. PGC-1α buffers ROS-mediated removal of mitochondria during myogenesis. Cell Death Dis 5:e1515.
15. Barker RA, Williams-Gray CH. 2016. The spectrum of clinical features seen with α synuclein pathology. Neuropathol Appl Neurobiol 42:6–19.
16. Bellucci A, Mercuri NB, Venneri A, Faustini G, Longhena F, Pizzi M, Missale C, Spano P. 2016. Parkinson's disease: from synaptic loss to connectome dysfunction. Neuropathol Appl Neurobiol 42:77–94.
17. Benskey MJ, Perez RG, Manfredsson FP. 2016. The contribution of α synuclein to neuronal survival and function: implications for Parkinson's disease. J Neurochem 137:331–359.
18. Bingol B, Sheng M. 2016. Mechanisms of mitophagy: PINK1, parkin, USP30, and beyond. Free Radic Biol Med 100:210–222.
19. Bingol B, Tea JS, Phu L, Reichelt M, Bakalarski CE, Song Q, Foreman O, Kirkpatrick DS, Sheng M. 2014. The mitochondrial deubiquitinase USP30 opposes parkin-mediated mitophagy. Nature 510:370–375.
20. +-induced oxidative stress act by modulating markers of apoptotic death in dopaminergic neurons. Cell Mol Neurobiol 29:1169–1180.
21. Brenmoehl J, Hoeflich A. 2013. Dual control of mitochondrial biogenesis by sirtuin 1 and sirtuin 3. Mitochondrion 13:755–761.
22. Büeler H. 2009. Impaired mitochondrial dynamics and function in the pathogenesis of Parkinson's disease. Exp Neurol 218:235–246.
23. Burré J, Sharma M, Tsetsenis T, Buchman V, Etherton MR, Südhof TC. 2010. Alpha-synuclein promotes SNARE-complex assembly in vivo and in vitro. Science 329:1663–1667.
24. + impairs autophagic clearance of α-synuclein by impairing the activity of dynein. Neuroreport 20:569–573.
25. + metabolism and SIRT1 activity. Nature 458:1056–1060.
26. Cantó C, Jiang LQ, Deshmukh AS, Mataki C, Coste A, Lagouge M, Zierath JR, Auwerx J. 2010. Interdependence of AMPK and SIRT1 for metabolic adaptation to fasting and exercise in skeletal muscle. Cell Metab 11:213–219.
27. Cappelletti G, Casagrande F, Calogero A, De Gregorio C, Pezzoli G, Cartelli D. 2015. Linking microtubules to Parkinson's disease: the case of parkin. Biochem Soc Trans 43:292–296.
28. Caulfield TR, Fiesel FC, Springer W. 2015. Activation of the E3 ubiquitin ligase parkin. Biochem Soc Trans 43:269–274.
29. Cencioni C, Spallotta F, Mai A, Martelli F, Farsetti A, Zeiher AM, Gaetano C. 2015. Sirtuin function in aging heart and vessels. J Mol Cell Cardiol 83:55–61.
30. Chang HC, Guarente L. 2014. SIRT1 and other sirtuins in metabolism. Trends Endocrinol Metab 25:138–145.
31. Chao J, Yu MS, Ho YS, Wang M, Chang RCC. 2008. Dietary oxyresveratrol prevents parkinsonian mimetic 6-hydroxydopamine neurotoxicity. Free Radic Biol Med 45:1019–1026.
32. Chao J, Li H, Cheng KW, Yu MS, Chang RCC, Wang M. 2010. Protective effects of pinostilbene, a resveratrol methylated derivative, against 6-hydroxydopamine-induced neurotoxicity in SH-SY5Y cells. J Nutr Biochem 21:482–489.
33. Chen D, Steele AD, Hutter G, Bruno J, Govindarajan A, Easlon E, Lin SJ, Aguzzi A, Lindquist S, Guarente L. 2008. The role of calorie restriction and SIRT1 in prion-mediated neurodegeneration. Exp Gerontol 43:1086–1093.
34. Chen X, Wales P, Quinti L, Zuo F, Moniot S, Herisson F, Rauf NA, Wang H, Silverman RB, Ayata C, Maxwell MM, Steegborn C, Schwarzschild MA, Outeiro TF, Kazantsev AG. 2015. The sirtuin-2 inhibitor AK7 is neuroprotective in models of Parkinson's disease but not amyotrophic lateral sclerosis and cerebral ischemia. PLoS One 10:e0116919.
35. Chung KW, Kim DH, Park MH, Choi YJ, Kim ND, Lee J, Yu BP, Chung HY. 2013. Recent advances in calorie restriction research on aging. Exp Gerontol 48:1049–1053.
36. Cohen HY, Miller C, Bitterman KJ, Wall NR, Hekking B, Kessler B, Howitz KT, Gorospe M, de Cabo R, Sinclair DA. 2004. Calorie restriction promotes mammalian cell survival by inducing the SIRT1 deacetylase. Science 305:390–392.
37. Connolly BS, Lang AE. 2014. Pharmacological treatment of Parkinson disease: a review. JAMA 311:1670–1683.
38. Cookson MR. 2012. Cellular effects of LRRK2 mutations. Biochem Soc Trans 40:1070–1073.
39. Cooper HM, Spelbrink JN. 2008. The human SIRT3 protein deacetylase is exclusively mitochondrial. Biochem J 411:279–285.
40. Costa A, Peppe A, Carlesimo GA, Zabberoni S, Scalici F, Caltagirone C, Angelucci F. 2015. Brain-derived neurotrophic factor serum levels correlate with cognitive performance in Parkinson's disease patients with mild cognitive impairment. Front Behav Neurosci 9:253.
41. Criollo A, et al. 2010. IKK connects autophagy to major stress pathways. Autophagy 6:189–191.
42. Cunningham CN, Baughman JM, Phu L, Tea JS, Yu C, Coons M, Kirkpatrick DS, Bingol B, Corn JE. 2015. USP30 and parkin homeostatically regulate atypical ubiquitin chains on mitochondria. Nat Cell Biol 17:160–169.
43. Das S, Mitrovsky G, Vasanthi HR, Das DK. 2014. Antiaging properties of a grape-derived antioxidant are regulated by mitochondrial balance of fusion and fission leading to mitophagy triggered by a signaling network of Sirt1-Sirt3-Foxo3-PINK1-parkin. Oxid Med Cell Longev 2014:345105.
44. Dasgupta B, Milbrandt J. 2007. Resveratrol stimulates AMP kinase activity in neurons. Proc Natl Acad Sci U S A 104:7217–7222.
45. Di Fruscia P, Zacharioudakis E, Liu C, Moniot S, Laohasinnarong S, Khongkow M, Harrison IF, Koltsida K, Reynolds CR, Schmidtkunz K, Jung M, Chapman KL, Steegborn C, Dexter DT, Sternberg MJE, Lam EWF, Fuchter MJ. 2015. The discovery of a highly selective 5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidin-4(3H)-one SIRT2 inhibitor that is neuroprotective in an in vitro Parkinson's disease model. Chem Med Chem 10:69–82.
46. Dominy JE, Lee Y, Gerhart-Hines Z, Puigserver P. 2010. Nutrient-dependent regulation of PGC-1α's acetylation state and metabolic function through the enzymatic activities of Sirt1/GCN5. Biochim Biophys Acta 1804:1676–1683.
47. Donmez G, Arun A, Chung CY, McLean PJ, Lindquist S, Guarente L. 2016. Author-initiated retraction: Donmez et al. SIRT1 Protects against α-synuclein aggregation by activating molecular chaperones. J Neurosci 36:4138.
48. Duan WJ, Li YF, Liu FL, Deng J, Wu YP, Yuan WL, Tsoi B, Chen JL, Wang Q, Cai SH, Kurihara H, He RR. 2016. A SIRT3/AMPK/autophagy network orchestrates the protective effects of transresveratrol in stressed peritoneal macrophages and RAW 264.7 macrophages. Free Radic Biol Med 95:230–242.
49. Durcan TM, Fon EA. 2015. The three ‘Ps of mitophagy: parkin, PINK1, and posttranslational modifications’. Genes Dev 29:989–999.
50. Ellis CE, Murphy EJ, Mitchell DC, Golovko MY, Scaglia F, Barceló-Coblijn GC, Nussbaum RL. 2005. Mitochondrial lipid abnormality and electron transport chain impairment in mice lacking α-synuclein. Mol Cell Biol 25:10190–10201.
51. Esteves AR, Cardoso SM. 2016. LRRK2 at the crossroad between autophagy and microtubule trafficking: insights into Parkinson's disease. Neuroscientist [E-pub ahead of print].
52. Esteves AR, Gozes I, Cardoso SM. 2014. The rescue of microtubule-dependent traffic recovers mitochondrial function in Parkinson's disease. Biochim Biophys Acta 1842:7–21.
53. Falkenberg KJ, Johnstone RW. 2014. Histone deacetylases and their inhibitors in cancer, neurological diseases, and immune disorders. Nat Rev Drug Discov 13:673–691.
54. Falone S, D'Alessandro A, Mirabilio A, Cacchio M, Di Ilio C, Di Loreto S, Amicarelli F. 2012. Late-onset running biphasically improves redox balance, energy-, and methylglyoxal-related status as well as SIRT1 expression in mouse hippocampus. PLoS One 7:e48334.
55. Ferretta A, Gaballo A, Tanzarella P, Piccoli C, Capitanio N, Nico B, Annese T, Di Paola M, Dell'aquila C, De Mari M, Ferranini E, Bonifati V, Pacelli C, Cocco T. 2014. Effect of resveratrol on mitochondrial function: implications in parkin-associated familiar Parkinson's disease. Biochim Biophys Acta 1842:902–915.
56. Gao J, Wang WY, Mao YW, Gräff J, Guan JS, Pan L, Mak G, Kim D, Su SC, Tsai LH. 2010. A novel pathway regulates memory and plasticity via SIRT1 and miR-134. Nature 466:1105–1109.
57. Gerhart-Hines Z, Rodgers JT, Bare O, Lerin C, Kim SH, Mostoslavsky R, Alt FW, Wu Z, Puigserver P. 2007. Metabolic control of muscle mitochondrial function and fatty acid oxidation through SIRT1/PGC-1α. EMBO J 26:1913–1923.
58. Godena VK, Brookes-Hocking N, Moller A, Shaw G, Oswald M, Sancho RM, Miller CCJ, Whitworth AJ, De Vos KJ. 2014. Increasing microtubule acetylation rescues axonal transport and locomotor deficits caused by LRRK2 Roc-COR domain mutations. Nat Commun 5:5245.
59. Gräff J, Kahn M, Samiei A, Gao J, Ota KT, Rei D, Tsai LH. 2013. A dietary regimen of caloric restriction or pharmacological activation of SIRT1 to delay the onset of neurodegeneration. J Neurosci 33:8951–8960.
60. Guedes A, Ludovico P, Sampaio-Marques B. 2016. Caloric restriction alleviates α-synuclein toxicity in aged yeast cells by controlling the opposite roles of Tor1 and Sir2 on autophagy. Mech Ageing Dev. doi: 10.1016/j.mad.2016.04.006 [E-pub ahead of print].
61. Haigis MC, Sinclair DA. 2010. Mammalian sirtuins: biological insights and disease relevance. Annu Rev Pathol 5:253–295.
62. Hailey DW, Rambold AS, Satpute-Krishnan P, Mitra K, Sougrat R, Kim PK, Lippincott-Schwartz J. 2010. Mitochondria supply membranes for autophagosome biogenesis during starvation. Cell 141:656–667.
63. Halliday G, Lees A, Stern M. 2011. Milestones in Parkinson's disease—clinical and pathologic features. Mov Disord 26:1015–1021.
64. Hamacher-Brady A, Brady NR. 2016. Mitophagy programs: mechanisms and physiological implications of mitochondrial targeting by autophagy. Cell Mol Life Sci 73:775–795.
65. Hamasaki M, Furuta N, Matsuda A, Nezu A, Yamamoto A, Fujita N, Oomori H, Noda T, Haraguchi T, Hiraoka Y, Amano A, Yoshimori T. 2013. Autophagosomes form at ER-mitochondria contact sites. Nature 495:389–393.
66. Hao CM, Haase VH. 2010. Sirtuins and their relevance to the kidney. J Am Soc Nephrol 21:1620–1627.
67. Hare DJ, Adlard PA, Doble PA, Finkelstein DI. 2013. Metallobiology of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine neurotoxicity. Metallomics 5:91–109.
68. Hariharan N, Maejima Y, Nakae J, Paik J, Depinho RA, Sadoshima J. 2010. Deacetylation of FoxO by Sirt1 plays an essential role in mediating starvation-induced autophagy in cardiac myocytes. Circ Res 107:1470–1482.
69. Hasegawa K, Yasuda T, Shiraishi C, Fujiwara K, Przedborski S, Mochizuki H, Yoshikawa K. 2016. Promotion of mitochondrial biogenesis by necdin protects neurons against mitochondrial insults. Nat Commun 7:10943.
70. Herskovits AZ, Guarente L. 2014. SIRT1 in neurodevelopment and brain senescence. Neuron 81:471–483.
71. Hirschey MD, Shimazu T, Goetzman E, Jing E, Schwer B, Lombard DB, Grueter CA, Harris C, Biddinger S, Ilkayeva OR, Stevens RD, Li Y, Saha AK, Ruderman NB, Bain JR, Newgard CB, Farese RV, Alt FW, Kahn CR, Verdin E. 2010. SIRT3 regulates mitochondrial fatty-acid oxidation by reversible enzyme deacetylation. Nature 464:121–125.
72. Hirschey MD, Shimazu T, Huang JY, Schwer B, Verdin E. 2011. SIRT3 regulates mitochondrial protein acetylation and intermediary metabolism. Cold Spring Harbor Symp Quant Biol 76:267–277.
73. Houtkooper RH, Pirinen E, Auwerx J. 2012. Sirtuins as regulators of metabolism and health span. Nat Rev Mol Cell Biol 13:225–238.
74. Howitz KT, Bitterman KJ, Cohen HY, Lamming DW, Lavu S, Wood JG, Zipkin RE, Chung P, Kisielewski A, Zhang LL, Scherer B, Sinclair DA. 2003. Small molecule activators of sirtuins extend Saccharomyces cerevisiae life span. Nature 425:191–196.
75. +-induced neuronal injury through Sirt3 mediated inhibition of mitochondrial dysfunction. Neurochem Int 79:57–64.
76. Hubbard BP, Gomes AP, Dai H, Li J, Case AW, Considine T, Riera TV, Lee JE, E SY, Lamming DW, Pentelute BL, Schuman ER, Stevens LA, Ling AJ, Armour SM, Michan S, Zhao H, Jiang Y, Sweitzer SM, Blum CA, Disch JS, Ng PY, Howitz KT, Rolo AP, Hamuro Y, Moss J, Perni RB, Ellis JL, Vlasuk GP, Sinclair DA. 2013. Evidence for a common mechanism of SIRT1 regulation by allosteric activators. Science 339:1216–1219.
77. Hyman C, Hofer M, Barde YA, Juhasz M, Yancopoulos GD, Squinto SP, Lindsay RM. 1991. BDNF is a neurotrophic factor for dopaminergic neurons of the substantia nigra. Nature 350:230–232.
78. Imai S, Armstrong CM, Kaeberlein M, Guarente L. 2000. Transcriptional silencing and longevity protein Sir2 is an NAD-dependent histone deacetylase. Nature 403:795–800.
79. + and sirtuins in aging and disease. Trends Cell Biol 24:464–471.
80. Iwahara T, Bonasio R, Narendra V, Reinberg D. 2012. SIRT3 functions in the nucleus in the control of stress-related gene expression. Mol Cell Biol 32:5022–5034.
81. Jadiya P, Chatterjee M, Sammi SR, Kaur S, Palit G, Nazir A. 2011. Sir-2.1 modulates “calorie-restriction-mediated” prevention of neurodegeneration in Caenorhabditis elegans: implications for Parkinson's disease. Biochem Biophys Res Commun 413:306–310.
82. +/NADH ratio and SIRT1 protein activation. J Biol Chem 287:19304–19314.
83. Jeong H, Cohen DE, Cui L, Supinski A, Savas JN, Mazzulli JR, Yates JR, Bordone L, Guarente L, Krainc D. 2011. Sirt1 mediates neuroprotection from mutant huntingtin by activation of the TORC1 and CREB transcriptional pathway. Nat Med 18:159–165.
84. Jiang M, et al. 2011. Neuroprotective role of Sirt1 in mammalian models of Huntington's disease through activation of multiple Sirt1 targets. Nat Med 18:153–158.
85. Jin F, Wu Q, Lu YF, Gong QH, Shi JS. 2008. Neuroprotective effect of resveratrol on 6-OHDA-induced Parkinson's disease in rats. Eur J Pharmacol 600:78–82.
86. Jin H, Kanthasamy A, Ghosh A, Anantharam V, Kalyanaraman B, Kanthasamy AG. 2014. Mitochondria-targeted antioxidants for treatment of Parkinson's disease: preclinical and clinical outcomes. Biochim Biophys Acta 1842:1282–1294.
87. Kalia LV, Kalia SK. 2015. α-Synuclein and Lewy pathology in Parkinson's disease. Curr Opin Neurol 28:375–381.
88. Kalia LV, Lang AE. 2015. Parkinson's disease. Lancet 386:896–912.
89. Kane LA, Lazarou M, Fogel AI, Li Y, Yamano K, Sarraf SA, Banerjee S, Youle RJ. 2014. PINK1 phosphorylates ubiquitin to activate parkin E3 ubiquitin ligase activity. J Cell Biol 205:143–153.
90. Kanfi Y, Naiman S, Amir G, Peshti V, Zinman G, Nahum L, Bar-Joseph Z, Cohen HY. 2012. The sirtuin SIRT6 regulates lifespan in male mice. Nature 483:218–221.
91. Kang HT, Hwang ES. 2009. Nicotinamide enhances mitochondria quality through autophagy activation in human cells. Aging Cell 8:426–438.
92. Kazlauskaite A, Kondapalli C, Gourlay R, Campbell DG, Ritorto MS, Hofmann K, Alessi DR, Knebel A, Trost M, Muqit MMK. 2014. Parkin is activated by PINK1-dependent phosphorylation of ubiquitin at Ser65. Biochem J 460:127–139.
93. Khan MM, Ahmad A, Ishrat T, Khan MB, Hoda MN, Khuwaja G, Raza SS, Khan A, Javed H, Vaibhav K, Islam F. 2010. Resveratrol attenuates 6-hydroxydopamine-induced oxidative damage and dopamine depletion in rat model of Parkinson's disease. Brain Res 1328:139–151.
94. Khan RS, Fonseca-Kelly Z, Callinan C, Zuo L, Sachdeva MM, Shindler KS. 2012. SIRT1 activating compounds reduce oxidative stress and prevent cell death in neuronal cells. Front Cell Neurosci 6:63.
95. Kitao Y, Ageta-Ishihara N, Takahashi R, Kinoshita M, Hori O. 2015. Transgenic supplementation of SIRT1 fails to alleviate acute loss of nigrostriatal dopamine neurons and gliosis in a mouse model of MPTP-induced parkinsonism. F1000Res 4:130.
96. Klein C, Westenberger A. 2012. Genetics of Parkinson's disease. Cold Spring Harbor Perspect Med 2:a008888.
97. Klingelhoefer L, Reichmann H. 2015. Pathogenesis of Parkinson disease: the gut–brain axis and environmental factors. Nat Rev Neurol 11:625–636.
98. Kondapalli C, Kazlauskaite A, Zhang N, Woodroof HI, Campbell DG, Gourlay R, Burchell L, Walden H, Macartney TJ, Deak M, Knebel A, Alessi DR, Muqit MMK. 2012. PINK1 is activated by mitochondrial membrane potential depolarization and stimulates parkin E3 ligase activity by phosphorylating serine 65. Open Biol 2:120080.
99. Kong X, Wang R, Xue Y, Liu X, Zhang H, Chen Y, Fang F, Chang Y. 2010. Sirtuin 3, a new target of PGC-1α, plays an important role in the suppression of ROS and mitochondrial biogenesis. PLoS One 5:e11707.
100. Koppula S, Kumar H, More SV, Kim BW, Kim IS, Choi DK. 2012. Recent advances on the neuroprotective potential of antioxidants in experimental models of Parkinson's disease. Int J Mol Sci 13:10608–10629.
101. Koronowski KB, Perez-Pinzon MA. 2015. Sirt1 in cerebral ischemia. Brain Circ 1:69–78.
102. Krey L, Lühder F, Kusch K, Czech-Zechmeister B, Könnecke B, Fleming Outeiro T, Trendelenburg G. 2015. Knockout of silent information regulator 2 (SIRT2) preserves neurological function after experimental stroke in mice. J Cereb Blood Flow Metab 35:2080–2088.
103. Lagouge M, Argmann C, Gerhart-Hines Z, Meziane H, Lerin C, Daussin F, Messadeq N, Milne J, Lambert P, Elliott P, Geny B, Laakso M, Puigserver P, Auwerx J. 2006. Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1α. Cell 127:1109–1122.
104. Lazarou M, Narendra DP, Jin SM, Tekle E, Banerjee S, Youle RJ. 2013. PINK1 drives parkin self-association and HECT-like E3 activity upstream of mitochondrial binding. J Cell Biol 200:163–172.
105. Le Grand JN, Gonzalez-Cano L, Pavlou MA, Schwamborn JC. 2015. Neural stem cells in Parkinson's disease: a role for neurogenesis defects in onset and progression. Cell Mol Life Sci 72:773–797.
106. Lee IH, Cao L, Mostoslavsky R, Lombard DB, Liu J, Bruns NE, Tsokos M, Alt FW, Finkel T. 2008. A role for the NAD-dependent deacetylase Sirt1 in the regulation of autophagy. Proc Natl Acad Sci U S A 105:3374–3379.
107. Lemasters JJ. 2014. Variants of mitochondrial autophagy: types 1 and 2 mitophagy and micromitophagy (type 3). Redox Biol 2:749–754.
108. Li Y, Xu W, McBurney MW, Longo VD. 2008. SirT1 inhibition reduces IGF-I/IRS-2/Ras/ERK1/2 signaling and protects neurons. Cell Metab 8:38–48.
109. Liang Q, Benavides GA, Vassilopoulos A, Gius D, Darley-Usmar V, Zhang J. 2013. Bioenergetic and autophagic control by Sirt3 in response to nutrient deprivation in mouse embryonic fibroblasts. Biochem J 454:249–257.
110. Lima LO, Scianni A, Rodrigues-de-Paula F. 2013. Progressive resistance exercise improves strength and physical performance in people with mild to moderate Parkinson's disease: a systematic review. J Physiother 59:7–13.
111. Lin SJ, Defossez PA, Guarente L. 2000. Requirement of NAD and SIR2 for life-span extension by calorie restriction in Saccharomyces cerevisiae. Science 289:2126–2128.
112. Lin TK, Chen SD, Chuang YC, Lin HY, Huang CR, Chuang JH, Wang PW, Huang ST, Tiao MM, Chen JB, Liou CW. 2014. Resveratrol partially prevents rotenone-induced neurotoxicity in dopaminergic SH-SY5Y cells through induction of heme oxygenase-1 dependent autophagy. Int J Mol Sci 15:1625–1646.
113. Liu L, Arun A, Ellis L, Peritore C, Donmez G. 2014. SIRT2 enhances 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced nigrostriatal damage via apoptotic pathway. Front Aging Neurosci 6:184.
114. Liu L, Peritore C, Ginsberg J, Kayhan M, Donmez G. 2015a. SIRT3 attenuates MPTP-induced nigrostriatal degeneration via enhancing mitochondrial antioxidant capacity. Neurochem Res 40:600–608.
115. Liu L, Peritore C, Ginsberg J, Shih J, Arun S, Donmez G. 2015b. Protective role of SIRT5 against motor deficit and dopaminergic degeneration in MPTP-induced mice model of Parkinson's disease. Behav Brain Res 281:215–221.
116. Lofrumento DD, Nicolardi G, Cianciulli A, De Nuccio F, La Pesa V, Carofiglio V, Dragone T, Calvello R, Panaro MA. 2014. Neuroprotective effects of resveratrol in an MPTP mouse model of Parkinson's-like disease: possible role of SOCS-1 in reducing proinflammatory responses. Innate Immun 20:249–260.
117. Long J, Gao H, Sun L, Liu J, Zhao-Wilson X. 2009. Grape extract protects mitochondria from oxidative damage and improves locomotor dysfunction and extends lifespan in a Drosophila Parkinson's disease model. Rejuvenation Res 12:321–331.
118. Lu KT, Ko MC, Chen BY, Huang JC, Hsieh CW, Lee MC, Chiou RYY, Wung BS, Peng CH, Yang YL. 2008. Neuroprotective effects of resveratrol on MPTP-induced neuron loss mediated by free radical scavenging. J Agric Food Chem 56:6910–6913.
119. Luthi-Carter R, Taylor DM, Pallos J, Lambert E, Amore A, Parker A, Moffitt H, Smith DL, Runne H, Gokce O, Kuhn A, Xiang Z, Maxwell MM, Reeves SA, Bates GP, Neri C, Thompson LM, Marsh JL, Kazantsev AG. 2010. SIRT2 inhibition achieves neuroprotection by decreasing sterol biosynthesis. Proc Natl Acad Sci U S A 107:7927–7932.
120. Mäkelä J, Tselykh TV, Kukkonen JP, Eriksson O, Korhonen LT, Lindholm D. 2016. Peroxisome proliferator-activated receptor-γ (PPARγ) agonist is neuroprotective and stimulates PGC-1α expression and CREB phosphorylation in human dopaminergic neurons. Neuropharmacology 102:266–275.
121. Martin I, Kim JW, Dawson VL, Dawson TM. 2014. LRRK2 pathobiology in Parkinson's disease. J Neurochem 131:554–565.
122. Masri S, Sassone-Corsi P. 2014. Sirtuins and the circadian clock: bridging chromatin and metabolism. Sci Signal 7:re6.
123. Maswood N, Young J, Tilmont E, Zhang Z, Gash DM, Gerhardt GA, Grondin R, Roth GS, Mattison J, Lane MA, Carson RE, Cohen RM, Mouton PR, Quigley C, Mattson MP, Ingram DK. 2004. Caloric restriction increases neurotrophic factor levels and attenuates neurochemical and behavioral deficits in a primate model of Parkinson's disease. Proc Natl Acad Sci U S A 101:18171–18176.
124. Matsuda N, Sato S, Shiba K, Okatsu K, Saisho K, Gautier CA, Sou YS, Saiki S, Kawajiri S, Sato F, Kimura M, Komatsu M, Hattori N, Tanaka K. 2010. PINK1 stabilized by mitochondrial depolarization recruits parkin to damaged mitochondria and activates latent parkin for mitophagy. J Cell Biol 189:211–221.
125. McLelland GL, Soubannier V, Chen CX, McBride HM, Fon EA. 2014. Parkin and PINK1 function in a vesicular trafficking pathway regulating mitochondrial quality control. EMBO J 33:282–295.
126. Michishita E, Park JY, Burneskis JM, Barrett JC, Horikawa I. 2005. Evolutionarily conserved and nonconserved cellular localizations and functions of human SIRT proteins. Mol Biol Cell 16:4623–4635.
127. Mimura T, Kaji Y, Noma H, Funatsu H, Okamoto S. 2013. The role of SIRT1 in ocular aging. Exp Eye Res 116:17–26.
128. Min SW, Cho SH, Zhou Y, Schroeder S, Haroutunian V, Seeley WW, Huang EJ, Shen Y, Masliah E, Mukherjee C, Meyers D, Cole PA, Ott M, Gan L. 2010. Acetylation of tau inhibits its degradation and contributes to tauopathy. Neuron 67:953–966.
129. Min SW, Sohn PD, Cho SH, Swanson RA, Gan L. 2013. Sirtuins in neurodegenerative diseases: an update on potential mechanisms. Front Aging Neurosci 5:53.
130. Mitchell SJ, Martin-Montalvo A, Mercken EM, Palacios HH, Ward TM, Abulwerdi G, Minor RK, Vlasuk GP, Ellis JL, Sinclair DA, Dawson J, Allison DB, Zhang Y, Becker KG, Bernier M, de Cabo R. 2014. The SIRT1 activator SRT1720 extends lifespan and improves health of mice fed a standard diet. Cell Rep 6:836–843.
131. Moon HE, Paek SH. 2015. Mitochondrial dysfunction in Parkinson's disease. Exp Neurobiol 24:103–116.
132. Mudò G, Mäkelä J, Di Liberto V, Tselykh TV, Olivieri M, Piepponen P, Eriksson O, Mälkiä A, Bonomo A, Kairisalo M, Aguirre JA, Korhonen L, Belluardo N, Lindholm D. 2012. Transgenic expression and activation of PGC-1α protect dopaminergic neurons in the MPTP mouse model of Parkinson's disease. Cell Mol Life Sci 69:1153–1165.
133. Nemoto S, Fergusson MM, Finkel T. 2005. SIRT1 functionally interacts with the metabolic regulator and transcriptional coactivator PGC-1{α}. J Biol Chem 280:16456–16460.
134. Ng F, Tang BL. 2013. Sirtuins' modulation of autophagy. J Cell Physiol 228:2262–2270.
135. Ng F, Wijaya L, Tang BL. 2015. SIRT1 in the brain-connections with aging-associated disorders and lifespan. Front Cell Neurosci 9:64.
136. +-dependent tubulin deacetylase. Mol Cell 11:437–444.
137. Olmos Y, Sánchez-Gómez FJ, Wild B, García-Quintans N, Cabezudo S, Lamas S, Monsalve M. 2013. SirT1 regulation of antioxidant genes is dependent on the formation of a FoxO3a/PGC-1α complex. Antioxid Redox Signal 19:1507–1521.
138. O'Malley KL. 2010. The role of axonopathy in Parkinson's disease. Exp Neurobiol 19:115–119.
139. Outeiro TF, Kontopoulos E, Altmann SM, Kufareva I, Strathearn KE, Amore AM, Volk CB, Maxwell MM, Rochet JC, McLean PJ, Young AB, Abagyan R, Feany MB, Hyman BT, Kazantsev AG. 2007. Sirtuin 2 inhibitors rescue α-synuclein-mediated toxicity in models of Parkinson's disease. Science 317:516–519.
140. Pacholec M, Bleasdale JE, Chrunyk B, Cunningham D, Flynn D, Garofalo RS, Griffith D, Griffor M, Loulakis P, Pabst B, Qiu X, Stockman B, Thanabal V, Varghese A, Ward J, Withka J, Ahn K. 2010. SRT1720, SRT2183, SRT1460, and resveratrol are not direct activators of SIRT1. J Biol Chem 285:8340–8351.
141. Pallos J, Bodai L, Lukacsovich T, Purcell JM, Steffan JS, Thompson LM, Marsh JL. 2008. Inhibition of specific HDACs and sirtuins suppresses pathogenesis in a Drosophila model of Huntington's disease. Hum Mol Genet 17:3767–3775.
142. Pangeni R, Sharma S, Mustafa G, Ali J, Baboota S. 2014. Vitamin E loaded resveratrol nanoemulsion for brain targeting for the treatment of Parkinson's disease by reducing oxidative stress. Nanotechnology 25:485102.
143. Papa L, Germain D. 2014. SirT3 regulates the mitochondrial unfolded protein response. Mol Cell Biol 34:699–710.
144. Patel VP, Chu CT. 2014. Decreased SIRT2 activity leads to altered microtubule dynamics in oxidatively-stressed neuronal cells: implications for Parkinson's disease. Exp Neurol 257:170–181.
145. Peng K, Tao Y, Zhang J, Wang J, Ye F, Dan G, Zhao Y, Cai Y, Zhao J, Wu Q, Zou Z, Cao J, Sai Y. 2016. Resveratrol regulates mitochondrial biogenesis and fission/fusion to attenuate rotenone-induced neurotoxicity. Oxid Med Cell Longev 2016:6705621.
146. Perdiz D, Mackeh R, Poüs C, Baillet A. 2011. The ins and outs of tubulin acetylation: more than just a posttranslational modification? Cell Signal 23:763–771.
147. Pi H, Xu S, Reiter RJ, Guo P, Zhang L, Li Y, Li M, Cao Z, Tian L, Xie J, Zhang R, He M, Lu Y, Liu C, Duan W, Yu Z, Zhou Z. 2015. SIRT3–SOD2–mROS-dependent autophagy in cadmium-induced hepatotoxicity and salvage by melatonin. Autophagy 11:1037–1051.
148. Price NL, Gomes AP, Ling AJ, Duarte FV, Martin-Montalvo A, North BJ, Agarwal B, Ye L, Ramadori G, Teodoro JS, Hubbard BP, Varela AT, Davis JG, Varamini B, Hafner A, Moaddel R, Rolo AP, Coppari R, Palmeira CM, de Cabo R, Baur JA, Sinclair DA. 2012. SIRT1 is required for AMPK activation and the beneficial effects of resveratrol on mitochondrial function. Cell Metab 15:675–690.
149. Pukaß K, Goldbaum O, Richter-Landsberg C. 2015. Mitochondrial impairment and oxidative stress compromise autophagosomal degradation of α-synuclein in oligodendroglial cells. J Neurochem 135:194–205.
150. Qin W, Yang T, Ho L, Zhao Z, Wang J, Chen L, Zhao W, Thiyagarajan M, MacGrogan D, Rodgers JT, Puigserver P, Sadoshima J, Deng H, Pedrini S, Gandy S, Sauve AA, Pasinetti GM. 2006. Neuronal SIRT1 activation as a novel mechanism underlying the prevention of Alzheimer disease amyloid neuropathology by calorie restriction. J Biol Chem 281:21745–21754.
151. Raynes R, Pombier KM, Nguyen K, Brunquell J, Mendez JE, Westerheide SD. 2013. The SIRT1 modulators AROS and DBC1 regulate HSF1 activity and the heat shock response. PLoS One 8:e54364.
152. Reed NA, Cai D, Blasius TL, Jih GT, Meyhofer E, Gaertig J, Verhey KJ. 2006. Microtubule acetylation promotes kinesin-1 binding and transport. Curr Biol 16:2166–2172.
153. Revilla S, Suñol C, García-Mesa Y, Giménez-Llort L, Sanfeliu C, Cristòfol R. 2014. Physical exercise improves synaptic dysfunction and recovers the loss of survival factors in 3 × Tg-AD mouse brain. Neuropharmacology 81:55–63.
154. Rodgers JT, Lerin C, Haas W, Gygi SP, Spiegelman BM, Puigserver P. 2005. Nutrient control of glucose homeostasis through a complex of PGC-1α and SIRT1. Nature 434:113–118.
155. Sampaio-Marques B, Felgueiras C, Silva A, Rodrigues M, Tenreiro S, Franssens V, Reichert AS, Outeiro TF, Winderickx J, Ludovico P. 2012. SNCA (α-synuclein)-induced toxicity in yeast cells is dependent on sirtuin 2 (Sir2)-mediated mitophagy. Autophagy 8:1494–1509.
156. Sansone L, Reali V, Pellegrini L, Villanova L, Aventaggiato M, Marfe G, Rosa R, Nebbioso M, Tafani M, Fini M, Russo MA, Pucci B. 2013. SIRT1 silencing confers neuroprotection through IGF-1 pathway activation. J Cell Physiol 228:1754–1761.
157. Satoh A, Brace CS, Ben-Josef G, West T, Wozniak DF, Holtzman DM, Herzog ED, Imai SI. 2010. SIRT1 promotes the central adaptive response to diet restriction through activation of the dorsomedial and lateral nuclei of the hypothalamus. J Neurosci 30:10220–10232.
158. Satoh A, Brace CS, Rensing N, Cliften P, Wozniak DF, Herzog ED, Yamada KA, Imai SI. 2013. Sirt1 extends life span and delays aging in mice through the regulation of Nk2 homeobox 1 in the DMH and LH. Cell Metab 18:416–430.
159. +-dependent histone deacetylase that translocates to the mitochondria upon cellular stress. Genes Dev 21:920–928.
160. Sengupta A, Molkentin JD, Yutzey KE. 2009. FoxO transcription factors promote autophagy in cardiomyocytes. J Biol Chem 284:28319–28331.
161. Seo JS, Moon MH, Jeong JK, Seol JW, Lee YJ, Park BH, Park SY. 2012. SIRT1, a histone deacetylase, regulates prion protein-induced neuronal cell death. Neurobiol Aging 33:1110–1120.
162. Shin BH, Lim Y, Oh HJ, Park SM, Lee SK, Ahnn J, Kim DH, Song WK, Kwak TH, Park WJ. 2013. Pharmacological activation of Sirt1 ameliorates polyglutamine-induced toxicity through the regulation of autophagy. PLoS One 8:e64953.
163. Shulman JM, De Jager PL, Feany MB. 2011. Parkinson's disease: genetics and pathogenesis. Annu Rev Pathol 6:193–222.
164. Someya S, Yu W, Hallows WC, Xu J, Vann JM, Leeuwenburgh C, Tanokura M, Denu JM, Prolla TA. 2010. Sirt3 mediates reduction of oxidative damage and prevention of age-related hearing loss under caloric restriction. Cell 143:802–812.
165. Song YM, Lee YH, Kim JW, Ham DS, Kang ES, Cha BS, Lee HC, Lee BW. 2015. Metformin alleviates hepatosteatosis by restoring SIRT1-mediated autophagy induction via an AMP-activated protein kinase-independent pathway. Autophagy 11:46–59.
166. Speelman AD, van de Warrenburg BP, van Nimwegen M, Petzinger GM, Munneke M, Bloem BR. 2011. How might physical activity benefit patients with Parkinson disease? Nat Rev Neurol 7:528–534.
167. Spina MB, Squinto SP, Miller J, Lindsay RM, Hyman C. 1992. Brain-derived neurotrophic factor protects dopamine neurons against 6-hydroxydopamine and N-methyl-4-phenylpyridinium ion toxicity: involvement of the glutathione system. J Neurochem 59:99–106.
168. Spires-Jones TL, Fox LM, Rozkalne A, Pitstick R, Carlson GA, Kazantsev AG. 2012. Inhibition of sirtuin 2 with sulfobenzoic acid derivative AK1 is nontoxic and potentially neuroprotective in a mouse model of frontotemporal dementia. Front Pharmacol 3:42.
169. Srivastava G, Dixit A, Yadav S, Patel DK, Prakash O, Singh MP. 2012. Resveratrol potentiates cytochrome P450 2 d22-mediated neuroprotection in maneb- and paraquat-induced parkinsonism in the mouse. Free Radic Biol Med 52:1294–1306.
170. Srivastava S, Haigis MC. 2011. Role of sirtuins and calorie restriction in neuroprotection: implications in Alzheimer's and Parkinson's diseases. Curr Pharm Des 17:3418–3433.
171. Storch A, Ludolph AC, Schwarz J. 2004. Dopamine transporter: involvement in selective dopaminergic neurotoxicity and degeneration. J Neural Transm 111:1267–1286.
172. St.-Pierre J, Drori S, Uldry M, Silvaggi JM, Rhee J, Jäger S, Handschin C, Zheng K, Lin J, Yang W, Simon DK, Bachoo R, Spiegelman BM. 2006. Suppression of reactive oxygen species and neurodegeneration by the PGC-1 transcriptional coactivators. Cell 127:397–408.
173. Takahashi-Niki K, Ganaha Y, Niki T, Nakagawa S, Kato-Ose I, Iguchi-Ariga SMM, Ariga H. 2016. DJ-1 activates SIRT1 through its direct binding to SIRT1. Biochem Biophys Res Commun 474:131–136.
174. Takizawa Y, Nakata R, Fukuhara K, Yamashita H, Kubodera H, Inoue H. 2015. The 4′-hydroxyl group of resveratrol is functionally important for direct activation of PPARα. PLoS One 10:e0120865.
175. Tan M, Tang C, Zhang Y, Cheng Y, Cai L, Chen X, Gao Y, Deng Y, Pan M. 2015. SIRT1/PGC-1α signaling protects hepatocytes against mitochondrial oxidative stress induced by bile acids. Free Radic Res 49:935–945.
176. Tang BL. 2011. Sirt1's systemic protective roles and its promise as a target in antiaging medicine. Transl Res 157:276–284.
177. Tang BL. 2016. Sirt1 and the mitochondria. Mol Cells 39:87–95.
178. +-dependent histone deacetylase SIRT1. J Biol Chem 282:6823–6832.
179. Tasdemir E, Maiuri MC, Galluzzi L, Vitale I, Djavaheri-Mergny M, D'Amelio M, Criollo A, Morselli E, Zhu C, Harper F, Nannmark U, Samara C, Pinton P, Vicencio JM, Carnuccio R, Moll UM, Madeo F, Paterlini-Brechot P, Rizzuto R, Szabadkai G, Pierron G, Blomgren K, Tavernarakis N, Codogno P, Cecconi F, Kroemer G. 2008. Regulation of autophagy by cytoplasmic p53. Nat Cell Biol 10:676–687.
180. Tomita T, Hamazaki J, Hirayama S, McBurney MW, Yashiroda H, Murata S. 2015. Sirt1-deficiency causes defective protein quality control. Sci Rep 5:12613.
181. Trancikova A, Tsika E, Moore DJ. 2012. Mitochondrial dysfunction in genetic animal models of Parkinson's disease. Antioxid Redox Signal 16:896–919.
182. Tseng AHH, Shieh SS, Wang DL. 2013. SIRT3 deacetylates FOXO3 to protect mitochondria against oxidative damage. Free Radic Biol Med 63:222–234.
183. Turner RS, Thomas RG, Craft S, van Dyck CH, Mintzer J, Reynolds BA, Brewer JB, Rissman RA, Raman R, Aisen PS, Alzheimer's Disease Cooperative Study. 2015. A randomized, double-blind, placebo-controlled trial of resveratrol for Alzheimer disease. Neurology 85:1383–1391.
184. Uhrbrand A, Stenager E, Pedersen MS, Dalgas U. 2015. Parkinson's disease and intensive exercise therapy—a systematic review and meta-analysis of randomized controlled trials. J Neurol Sci 353:9–19.
185. Ur Rasheed MS, Tripathi MK, Mishra AK, Shukla S, Singh MP. 2016. Resveratrol protects from toxin-induced parkinsonism: plethora of proofs hitherto petty translational value. Mol Neurobiol 53:2751–2760.
186. Valle I, Alvarez-Barrientos A, Arza E, Lamas S, Monsalve M. 2005. PGC-1α regulates the mitochondrial antioxidant defense system in vascular endothelial cells. Cardiovasc Res 66:562–573.
187. van Ham TJ, Thijssen KL, Breitling R, Hofstra RMW, Plasterk RHA, Nollen EAA. 2008. C. elegans model identifies genetic modifiers of α-synuclein inclusion formation during aging. PLoS Genet 4:e1000027.
188. Van Laar VS, Berman SB. 2013. The interplay of neuronal mitochondrial dynamics and bioenergetics: implications for Parkinson's disease. Neurobiol Dis 51:43–55.
189. Vargas KJ, Makani S, Davis T, Westphal CH, Castillo PE, Chandra SS. 2014. Synucleins regulate the kinetics of synaptic vesicle endocytosis. J Neurosci 34:9364–9376.
190. Verdin E, Hirschey MD, Finley LWS, Haigis MC. 2010. Sirtuin regulation of mitochondria: energy production, apoptosis, and signaling. Trends Biochem Sci 35:669–675.
191. Wang SJ, Zhao XH, Chen W, Bo N, Wang XJ, Chi ZF, Wu W. 2015. Sirtuin 1 activation enhances the PGC-1α/mitochondrial antioxidant system pathway in status epilepticus. Mol Med Rep 11:521–526.
192. Wang Y, Xu H, Fu Q, Ma R, Xiang J. 2011. Protective effect of resveratrol derived from Polygonum cuspidatum and its liposomal form on nigral cells in parkinsonian rats. J Neurol Sci 304:29–34.
193. Watanabe S, Ageta-Ishihara N, Nagatsu S, Takao K, Komine O, Endo F, Miyakawa T, Misawa H, Takahashi R, Kinoshita M, Yamanaka K. 2014. SIRT1 overexpression ameliorates a mouse model of SOD1-linked amyotrophic lateral sclerosis via HSF1/HSP70i chaperone system. Mol Brain 7:62.
194. Webster BR, Scott I, Han K, Li JH, Lu Z, Stevens MV, Malide D, Chen Y, Samsel L, Connelly PS, Daniels MP, McCoy JP, Combs CA, Gucek M, Sack MN. 2013. Restricted mitochondrial protein acetylation initiates mitochondrial autophagy. J Cell Sci 126:4843–4849.
195. Westerheide SD, Anckar J, Stevens SM, Sistonen L, Morimoto RI. 2009. Stress-inducible regulation of heat shock factor 1 by the deacetylase SIRT1. Science 323:1063–1066.
196. Wood JG, Rogina B, Lavu S, Howitz K, Helfand SL, Tatar M, Sinclair D. 2004. Sirtuin activators mimic caloric restriction and delay ageing in metazoans. Nature 430:686–689.
197. Wu PF, Xie N, Zhang JJ, Guan XL, Zhou J, Long LH, Li YL, Xiong QJ, Zeng JH, Wang F, Chen JG. 2013. Resveratrol preconditioning increases methionine sulfoxide reductases A expression and enhances resistance of human neuroblastoma cells to neurotoxins. J Nutr Biochem 24:1070–1077.
198. Wu Y, Li X, Zhu JX, Xie W, Le W, Fan Z, Jankovic J, Pan T. 2011. Resveratrol-activated AMPK/SIRT1/autophagy in cellular models of Parkinson's disease. Neurosignals 19:163–174.
199. Xiong N, Long X, Xiong J, Jia M, Chen C, Huang J, Ghoorah D, Kong X, Lin Z, Wang T. 2012. Mitochondrial complex I inhibitor rotenone-induced toxicity and its potential mechanisms in Parkinson's disease models. Crit Rev Toxicol 42:613–632.
200. Ye Q, Huang W, Li D, Si E, Wang J, Wang Y, Chen C, Chen X. 2016. Overexpression of PGC-1α influences mitochondrial signal transduction of dopaminergic neurons. Mol Neurobiol 53:3756–3770.
201. Yuan Y, Cruzat VF, Newsholme P, Cheng J, Chen Y, Lu Y. 2016. Regulation of SIRT1 in aging: roles in mitochondrial function and biogenesis. Mech Ageing Dev 155:10–21.
202. Zhang F, Wang S, Gan L, Vosler PS, Gao Y, Zigmond MJ, Chen J. 2011. Protective effects and mechanisms of sirtuins in the nervous system. Prog Neurobiol 95:373–395.
203. Zhang JY, Deng YN, Zhang M, Su H, Qu QM. 2016a. SIRT3 acts as a neuroprotective agent in rotenone-induced Parkinson cell model. Neurochem Res 41:1761–1773.
204. Zhang X, Ren X, Zhang Q, Li Z, Ma S, Bao J, Li Z, Bai X, Zheng L, Zhang Z, Shang S, Zhang C, Wang C, Cao L, Wang Q, Ji J. 2016b. PGC-1α/ERRα-Sirt3 pathway regulates DAergic neuronal death by directly deacetylating SOD2 and ATP synthase β. Antioxid Redox Signal 24:312–328.
205. + metabolism and signaling to the control of cellular functions. Biochim Biophys Acta 1804:1666–1675.
206. Zhao Y, Luo P, Guo Q, Li S, Zhang L, Zhao M, Xu H, Yang Y, Poon W, Fei Z. 2012. Interactions between SIRT1 and MAPK/ERK regulate neuronal apoptosis induced by traumatic brain injury in vitro and in vivo. Exp Neurol 237:489–498.
207. Ziebell M, Khalid U, Klein AB, Aznar S, Thomsen G, Jensen P, Knudsen GM. 2012. Striatal dopamine transporter binding correlates with serum BDNF levels in patients with striatal dopaminergic neurodegeneration. Neurobiol Aging 33:428.e1–428.e5.
208. Zocchi L, Sassone-Corsi P. 2012. SIRT1-mediated deacetylation of MeCP2 contributes to BDNF expression. Epigenetics 7:695–700.
209. Zou XD, Guo SQ, Hu ZW, Li WL. 2016. NAMPT protects against 6-hydroxydopamine-induced neurotoxicity in PC12 cells through modulating SIRT1 activity. Mol Med Rep 13:4058–4064.
210. Zuccato C, Cattaneo E. 2009. Brain-derived neurotrophic factor in neurodegenerative diseases. Nat Rev Neurol 5:311–322.